Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remternetug in Early Symptomatic Alzheimer's Disease
NCT05463731Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2022
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of remternetug in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Started Aug 2022; status: completed.
02
Drugs
remternetug
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05463731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05463731.